The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.
A user shared their 4-month progress using oral minoxidil, finasteride, and derma rolling for hair loss. They reported positive results and expressed gratitude for the treatment.
The user has been using 0.5mg finasteride daily for 4 years and is considering adding minoxidil, either oral or topical, to improve hairline density. They are also contemplating a hair transplant and have been using derma rolling and ketoconazole inconsistently.
Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.
Hair loss progress in 4.5 months using dutasteride 3x/week, topical minoxidil 1-2x daily, and microneedling 2x/month. Users praised the significant improvement.
User shows temple area progress after hair transplant, using DUT every other day and oral Min 2.5 daily. Another user asks about number of grafts and cost.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.
A user reported significant hair improvement using ginseng oil along with Minoxidil, finasteride, RU58841, and microneedling, leading them to cancel a hair transplant. Other users requested more details and proof.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
Hair regrowth using finasteride 1mg daily and topical minoxidil twice daily, with a hair transplant after three years, showed significant improvement over four years. The user is satisfied with the results despite not having access to oral minoxidil.
User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hair follicles.
A user shared their 15-month hair regrowth progress using finasteride, minoxidil, biotin, increased protein intake, and derma rolling. They also improved their lifestyle by working out, quitting smoking, drinking less, and getting better sleep.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
The conclusion of the conversation is that the user experienced noticeable regrowth of hair after using dutasteride as a single treatment for about 1.5 years. No before photos were available.
The conversation is about a user who had a hair transplant with 2,850 grafts and switched from finasteride and topical minoxidil to oral minoxidil and dutasteride for better results. They are hopeful for full results in a year.
A 26-year-old male shared progress pictures after 4 months of treating hair loss with finasteride (1.25 mg on Mondays, Wednesdays, and Fridays), topical minoxidil twice daily, ketoconazole shampoo twice weekly, and weekly microneedling at 1.5 mm. He is seeing hair growth improvement, especially in the front, and is considering hair grafts for the crown area if necessary for more density.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
A user underwent a 2,550 FUE hair transplant and started taking dutasteride 0.5mg. They previously tried RU58841, minoxidil, and microneedling but avoided finasteride and dutasteride due to side effects.
A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.
The user is using oral minoxidil and finasteride for hair loss and plans to add topical minoxidil and a dermaroller. They also use ketoconazole shampoo to support hair regrowth.
A user shared their positive experience with a 2200 graft FUE hair transplant at DiStefano Hair Restoration in Worcester, MA, praising Dr. Heinis and his staff for their care. The user is also using oral Dutasteride, topical Minoxidil, and vitamins D and B.
The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.
The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.
The conversation is about finding a source to buy RU58841 in Germany, specifically looking for a PG-free option. Users suggest buying powder and mixing it themselves, with one user recommending a specific website.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.